Oral Cyclic Peptides: Why Binding Strength Is Only Part of the Design Problem

Binding is only one property — A compound can bind its target tightly and still perform poorly, because binding affinity says nothing about whether the molecule reaches the target intact. Permeability and stability are separate properties that must be optimised alongside binding.

undefined

Permeability — Passive permeability across a membrane depends on size, polarity, hydrogen-bonding capacity and conformational flexibility. Peptides above a certain size tend to be poor candidates for passive permeation unless a deliberate design strategy is applied.

undefined

Stability — Proteolytic stability depends on the sequence and on the modifications present. Cyclisation, D-amino acid substitution and N-methylation can each change how a sequence is recognised by proteases, and each carries a cost in synthesis complexity.

undefined

Conformational constraint — Cyclisation constrains the conformational ensemble, which can both improve target binding by pre-organising the active conformation and change permeability by reducing the number of exposed polar groups. The two effects are not independent and are difficult to optimise in isolation.

undefined

Why the trade-off resists simple optimisation — Improving one property commonly degrades another: rigidifying the backbone for permeability can reduce solubility, and increasing lipophilicity for membrane passage can increase plasma protein binding. Design work that optimises a single property in isolation tends to move the problem rather than solve it.

undefined

The practical consequence — The useful design question is not whether a cyclic peptide can bind, but whether a specific set of modifications can deliver acceptable permeability and stability at the same time. That question is answered by measurement across a panel of properties rather than by binding data alone.

undefined